- Clearmind Medicine (CMND) has announced positive pre-clinical results for its treatment for cocaine addiction using MEAI, its novel psychedelic molecule.
- The results followed Clearmind’s recent news regarding filing a provisional patent application related to cocaine addiction
- Clearmind is a biotech company focused on the discovery and development of safe and novel psychedelic-derived therapeutics to treat alcohol use disorder and other challenges
- Clearmind Medicine Inc. opened trading at $0.35 per share
Clearmind Medicine (CMND) has announced positive pre-clinical results for its treatment for cocaine addiction using MEAI, its novel psychedelic molecule. Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer commented on the news.
“This exciting research on MEAI could go a long way in helping those who need it. While effective treatments for opioid addictions have been available, this could be the first dedicated treatment for cocaine addiction, which is a global crisis.”
Results from the study suggest a potential role for MEAI in abolishing cocaine-induced conditioned place preference and eliminating heightened craving, and that the compound was not itself addictive. The 5 mg/kg dose was found the most effective dose and selected for further study.
The results followed Clearmind’s recent news regarding filing a provisional patent application related to cocaine addiction.
“Once again, MEAI has shown the potential to become a game changer in the field of addiction treatments” Zuloff- Shani added.
“We intend to further explore the potential of MEAI as an anti-cocaine addiction treatment.”
Clearmind is a new biotech company focused on the discovery and development of safe and novel psychedelic-derived therapeutics to treat alcohol use disorder and other pressing health challenges.
The Israeli-Canadian company holds several patents for the non-hallucinogenic compound MEAI (5-methoxy-2-aminoindane, a novel psychoactive substance).
The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Clearmind Medicine Inc. (CMND) opened trading at C$0.35.
